Skip to search formSkip to main contentSkip to account menu

Alimta

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
In patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC), first-line pembrolizumab (Keytruda, Merck) with… 
2010
2010
Autoři se zabývaji Registrem Alimta - nemalobuněcný karcinom plic (NSCLC) a maligni pleuralni mezoteliom (MPM) 
2007
2007
10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients 
2007
2007
A135 This pilot study investigated the mechanism of action of PDX and its differences from other antifolates, and compared the in… 
2005
2005
Malignant Pleural Mesothelioma is regarded as a tumour, which lacks chemo-sensitivity. However, patients are able to benefit from… 
2005
2005
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
Review
2004
Review
2004
No known cure exists for malignant pleural mesothelioma (MPM). The prognosis for patients with this relatively rare, asbestos… 
2001
2001
The impact of p53 status on cellular sensitivity to antifolate drugs has been examined in seven human cell lines (A549, MCF7, T…